

**NOTIFICATION**

*Addendum*

The following communication, dated 8 June 2021, is being circulated at the request of the delegation of Brazil.

**Title:** Amendment of Resolution – RDC number 283, 17 May 2019

<b>Reason for Addendum:</b>	
<input type="checkbox"/>	Comment period changed - date:
<input type="checkbox"/>	Notified measure adopted - date:
<input checked="" type="checkbox"/>	Notified measure published - date: 02 June 2021
<input checked="" type="checkbox"/>	Notified measure enters into force - date: 02 June 2021
<input type="checkbox"/>	Text of final measure available from <sup>1</sup> :
<input type="checkbox"/>	Notified measure withdrawn or revoked - date: Relevant symbol if measure re-notified:
<input checked="" type="checkbox"/>	Content or scope of notified measure changed <a href="https://www.in.gov.br/web/dou/-/resolucao-rdc-n-500-de-27-de-maio-de-2021-323570081">https://www.in.gov.br/web/dou/-/resolucao-rdc-n-500-de-27-de-maio-de-2021-323570081</a> <a href="http://antigo.anvisa.gov.br/legislacao#/visualizar/451744">http://antigo.anvisa.gov.br/legislacao#/visualizar/451744</a> New deadline for comments (if applicable):
<input type="checkbox"/>	Interpretive guidance issued and text available from:
<input type="checkbox"/>	Other:

**Description:**

ANVISA Resolution RDC number 283, 4 May 2019, which establishes technical requirements for investigation, control and elimination of nitrosamines potentially carcinogenic in active pharmaceutical ingredients (IFA) which are angiotensin II receptor antagonists; and is applied to companies that manufacture, import and fractionate active pharmaceutical ingredients (IFA), - previously notified through G/TBT/N/BRA/871, was amended by the Resolution - RDC number 500, 27 May 2021.

The new text establishes that:

The final text is available only in Portuguese and can be downloaded at:

\_\_\_\_\_

<http://antigo.anvisa.gov.br/legislacao#/visualizar/451744>

---